Hypoxia inducible factor‐1 promotes liver fibrosis in nonalcoholic fatty liver disease by activating PTEN/p65 signaling pathway

2019 ◽  
Vol 120 (9) ◽  
pp. 14735-14744 ◽  
Author(s):  
Jie Han ◽  
Yaping He ◽  
Hui Zhao ◽  
Xiaowei Xu
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Signaling Pathway ◽  
Fatty Liver Disease ◽  
Hypoxia Inducible Factor ◽  
Nonalcoholic Fatty Liver ◽  
Hypoxia Inducible Factor 1

scholarly journals Hepatocyte Hypoxia Inducible Factor-1 Mediates the Development of Liver Fibrosis in a Mouse Model of Nonalcoholic Fatty Liver Disease

PLoS ONE ◽  
2016 ◽  
Vol 11 (12) ◽  
pp. e0168572 ◽  
Author(s):  
Omar A. Mesarwi ◽  
Mi-Kyung Shin ◽  
Shannon Bevans-Fonti ◽  
Christina Schlesinger ◽  
Janet Shaw ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Mouse Model ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Hypoxia Inducible Factor ◽  
Nonalcoholic Fatty Liver ◽  
Hypoxia Inducible Factor 1

scholarly journals Prevalence of clinically relevant liver fibrosis due to nonalcoholic fatty liver disease in Indian individuals with type 2 diabetes

JGH Open ◽  
2021 ◽  
Author(s):  
Mohammad Shafi Kuchay ◽  
Narendra Singh Choudhary ◽  
Sunil Kumar Mishra ◽  
Tarannum Bano ◽  
Sakshi Gagneja ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver

scholarly journals SGL 121 Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism Through AMPK Signaling Pathway

2020 ◽  
Vol 21 (12) ◽  
pp. 4534
Author(s):  
Da Eun Kim ◽  
Bo Yoon Chang ◽  
Byeong Min Jeon ◽  
Jong In Baek ◽  
Sun Chang Kim ◽  
...  
Keyword(s):  
Lipid Metabolism ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Signaling Pathway ◽  
Hepg2 Cells ◽  
Fatty Liver Disease ◽  
Fatty Acid Synthase ◽  
Density Lipoprotein ◽  
Nonalcoholic Fatty Liver

A ginsenoside F2-enhanced mixture (SGL 121) increases the content of ginsenoside F2 by biotransformation. In the present study, we investigated the effect of SGL 121 on nonalcoholic fatty liver disease (NAFLD) in vitro and in vivo. High-fat, high-carbohydrate-diet (HFHC)-fed mice were administered SGL 121 for 12 weeks to assess its effect on improving NAFLD. In HepG2 cells, SGL 121 acted as an antioxidant, a hepatoprotectant, and had an anti-lipogenic effect. In NAFLD mice, SGL 121 significantly improved body fat mass; levels of hepatic triglyceride (TG), hepatic malondialdehyde (MDA), serum total cholesterol (TC), high-density lipoprotein (HDL), and low-density lipoprotein (LDL); and activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). In HepG2 cells, induced by oxidative stress, SGL 121 increased cytoprotection, inhibited reactive oxygen species (ROS) production, and increased antioxidant enzyme activity. SGL 121 activated the Nrf2/HO-1 signaling pathway and improved lipid accumulation induced by free fatty acids (FFA). Sterol regulatory element-binding protein-1 (SREBP-1) and fatty acid synthase (FAS) expression was significantly reduced in NAFLD-induced liver and HepG2 cells treated with SGL 121. Moreover, SGL 121 activated adenosine monophosphate-activated protein kinase (AMPK), which plays an important role in the regulation of lipid metabolism. The effect of SGL 121 on the improvement of NAFLD seems to be related to its antioxidant effects and activation of AMPK. In conclusion, SGL 121 can be potentially used for the treatment of NAFLD.

M1988 Noninvasive Markers of Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease (NAFLD)

2010 ◽  
Vol 138 (5) ◽  
pp. S-453 ◽  
Author(s):  
Naim Alkhouri ◽  
Christine A. Carter-Kent ◽  
Anna Alisi ◽  
Ariel E. Feldstein ◽  
Valerio Nobili
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver ◽  
Noninvasive Markers

scholarly journals Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease

Hepatology ◽  
2010 ◽  
Vol 51 (4) ◽  
pp. 1209-1217 ◽  
Author(s):  
Luca Valenti ◽  
Ahmad Al-Serri ◽  
Ann K. Daly ◽  
Enrico Galmozzi ◽  
Raffaela Rametta ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver

scholarly journals Noninvasive diagnosis of liver fibrosis in patients with nonalcoholic fatty liver disease

2017 ◽  
Vol 51 (3) ◽  
pp. 188-195 ◽  
Author(s):  
Yu.M. Stepanov ◽  
N.V. Nedzvetskaya ◽  
V.B. Yagmur ◽  
I.A. Klenina ◽  
N.Yu. Oshmyanskaya
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Noninvasive Diagnosis ◽  
Nonalcoholic Fatty Liver
Sign in / Sign up

Export Citation Format

Share Document